Every 10-Q that Lucid Diagnostics Inc. (LUCD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.
Lucid Diagnostics Inc. reported higher EsoGuard testing revenue but continued significant losses for the quarter and six months ended June 30, 2026. Revenue reached $1.5 million for the quarter and $2.7 million for the first half of 2026, up from $1.2 million and $2.0 million a year earlier.
The company recorded a first-half net loss attributable to common stockholders of $38.3 million and used $23.4 million of cash in operating activities. Cash was $33.4 million and working capital about $9.1 million as of June 30, 2026, including $23.5 million of current 2024 Senior Secured Convertible Notes. Management states that recurring losses, cash burn, and upcoming obligations raise substantial doubt about the company’s ability to continue as a going concern without additional capital and expanded reimbursement.
Lucid raised capital through an April 2026 registered direct offering of 18,000,000 shares for net proceeds of $16.8 million and an at-the-market program adding about $5.3 million. The $21.975 million 12% 2024 Convertible Notes had a fair value of $23.5 million and carry covenants, including a minimum cash requirement of $5.0 million. The company is pursuing Medicare coverage for EsoGuard, obtained its first positive coverage policy from a laboratory benefit manager, and secured a U.S. Department of Veterans Affairs contract.
Lucid Diagnostics Inc. reported higher Q1 2026 revenue but continued large losses and liquidity pressure. Revenue rose to about $1.3 million from $0.8 million a year earlier, driven by more EsoGuard test billings.
The net loss attributable to common stockholders was about $23.6 million versus $36.0 million in Q1 2025, or $(0.17) per share compared with $(0.52). Operating cash outflow was roughly $12.1 million, leaving cash of about $27.9 million and working capital near $2.0 million as of March 31, 2026.
Lucid carries $21.975 million face value of Senior Secured Convertible Notes, measured at a fair value of $25.2 million, and must maintain at least $5.0 million in available cash while they are significantly outstanding. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern without more revenue and capital.
To bolster liquidity, Lucid raised approximately $5.3 million net in Q1 2026 through its at-the-market equity program and, after quarter-end, about $16.8 million net from an April 2026 registered direct offering of 18,000,000 shares at $1.00 per share. The company is seeking Medicare coverage for EsoGuard, has a recent U.S. Department of Veterans Affairs contract, and obtained a waiver through August 22, 2026 on a potential default tied to not yet receiving a positive Medicare decision.
Lucid Diagnostics (LUCD) reported Q3 2025 results, highlighting modest revenue and continued investment alongside a formal going concern warning. Revenue was $1.2 million for the quarter and $3.2 million year-to-date, reflecting ongoing early commercialization of EsoGuard testing. Operating loss was $11.8 million in Q3; net loss attributable to common stockholders was $10.4 million, or $0.10 per share.
Cash stood at $47.3 million as of September 30, 2025, with working capital of $23.6 million and operating cash outflows of $33.9 million for the nine months. Management states that substantial doubt exists about the company’s ability to continue as a going concern within one year, absent materially higher reimbursement-driven revenue or additional financing.
To fund operations, Lucid raised capital through equity offerings—$14.9 million (March), $16.2 million (April), and $27.0 million (September)—and has $21.975 million face value of 12% Senior Secured Convertible Notes (fair value $22.3 million; $1.00 conversion price). Common shares issued and outstanding were 130,924,686 as of September 30, 2025; 137,683,002 as of November 7, 2025.
Lucid Diagnostics (LUCD) is a commercial-stage cancer-prevention diagnostics company selling the EsoGuard test with EsoCheck sampling. For the three and six months ended June 30, 2025 the company recognized $1.16 million and $1.99 million of revenue, respectively, while reporting a net loss attributable to common stockholders of $7.9 million for the quarter and $43.9 million for the six months. Operating activities used $23.0 million of cash in the first half of 2025, leaving $31.1 million of cash and approximately $4.4 million of working capital as of June 30, 2025.
Key balance sheet and financing items include total assets of $38.7 million, stockholders' equity of $7.9 million, and Senior Secured Convertible Notes with $21.975 million face value carried at fair value of $25.3 million (conversion price $1.00; 12% stated interest). Management discloses substantial doubt about going concern absent increased reimbursement, revenue growth or additional financing. Recent developments include two equity raises in March and April 2025 netting ~$31.0 million, an ATM up to $25.0 million, Highmark coverage in New York effective May 26, 2025, MolDx LCD reconsideration (CAC on Sept 4, 2025), multiple peer-reviewed publications, and an $8.0 million NIH R01 award to CWRU investigators.